BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tambiciclib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tambiciclib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04588922-3077@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Tambiciclib: Phase 1/2 readout est. (NCT04588922)
DESCRIPTION:Tambiciclib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study
  of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in P
 atients With Hematologic Malignancies and High-Risk Newly Diagnosed AML\nE
 stimated primary completion: 30 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tambiciclib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04588922
URL:https://assetmemo.bio/drug/tambiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06375733-3077@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tambiciclib: Phase 1/2 readout est. (NCT06375733)
DESCRIPTION:Tambiciclib\, phase 1/2.\nStudy: A Study of GFH009 in Combinati
 on With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL\nEstima
 ted primary completion: 31 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tambiciclib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06375733
URL:https://assetmemo.bio/drug/tambiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
